Open AccessAntimitochondrial autoantibodies in anti‐glomerular basement membrane disease
Author(s) -
MARRIOTT J. B.,
OLIVEIRA D. B. G.
Publication year - 1993
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1993.tb07976.x
Subject(s) - autoantibody , polyclonal antibodies , primary biliary cirrhosis , immunology , pathogenesis , biology , glomerulonephritis , goodpasture syndrome , basement membrane , antibody , glomerular basement membrane , pathology , medicine , endocrinology , kidney
SUMMARY Anti‐glomerular basement membrane (GBM) disease is characterized by the production of an autoantibody with very restricted specificity, with no evidence of polyclonal B cell activation. It was therefore surprising to find that in a solid‐phase ELISA a proportion of anti‐GBM sera showed significant binding to pyruvate dehydrogenase (PDH), a reactivity usually associated with the antimitochondrial autoantibodies (AM A) found in primary biliary cirrhosis (PBC). The specificity of this reactivity was confirmed by inhibition and competition experiments. The AMA found in anti‐GBM sera were of much lower affinity than those found in PBC sera, and recognized a more restricted set of species (mainly the 55‐kD and occasionally the 74‐kD component of PDH). However, it was possible to block the binding in a Western blot of an anti‐GBM serum to both the 55‐kD and 74‐kD species with F(ab') 2 fragments prepared from a PBC serum. Although AMA have been found in diseases other than PBC, such diseases have usually been characterized by polyclonal B cell activation. The stimulus to the production of AMA in anti‐GBM disease, and their significance in pathogenesis (if any), are unknown.